Stocks Health care BLSM
Health careBlossomHill Therapeutics, Inc. (BLSM)
At June 30, 2026 it held $95.4M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on September 18, 2026.
Key facts about BlossomHill Therapeutics, Inc.
- Net worth
- BlossomHill Therapeutics, Inc. has a market value (market cap) of $439M at the latest share price. A company's "net worth" usually means this market value or the shareholders' equity on its balance sheet.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on September 18, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
What BlossomHill Therapeutics, Inc. does
BlossomHill Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations).
Earnings: every quarter and the next report date
Latest SEC filings
What BlossomHill Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 18, 2026Quarterly report10-Q · period to June 30, 2026BlossomHill Therapeutics advanced its oncology pipeline and completed an IPO to fund operations for at least 12 months.Diluted EPS -$8.75 versus -$5.51.
- September 18, 2026Quarterly results8-KBlossomHill Therapeutics reported its second quarter 2026 financial results and clinical pipeline updates.
- September 15, 2026
- August 18, 2026Activist stake (5% or more) SCHEDULE 13D
- August 17, 2026Passive stake (5% or more) SCHEDULE 13G
- August 14, 2026Passive stake (5% or more) SCHEDULE 13G
- August 13, 2026Activist stake (5% or more) SCHEDULE 13D
- August 10, 2026
- August 10, 2026
- August 6, 2026Form S-1MEF filing S-1MEF
Insider trades
What the people running BlossomHill Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| August 10, 2026 | Orbimed Advisors LLCDirector | Exercised optionsindirect | 1,039,996 | - |
| August 10, 2026 | Orbimed Advisors LLCDirector | Exercised optionsindirect | 1,049,283 | - |
| August 10, 2026 | Orbimed Advisors LLCDirector | Boughtindirect | 625,000 | $10M |
| August 10, 2026 | Gordon Carl LDirector | Exercised optionsindirect | 1,039,996 | - |
| August 10, 2026 | Gordon Carl LDirector | Exercised optionsindirect | 1,049,283 | - |
| August 10, 2026 | Gordon Carl LDirector | Boughtindirect | 625,000 | $10M |
| August 10, 2026 | Chen BihuaDirector, 10% owner | Exercised optionsindirect | 1,599,993 | - |
| August 10, 2026 | Chen BihuaDirector, 10% owner | Exercised optionsindirect | 1,701,541 | - |
Who owns BLSM
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Chen Bihua13D, may seek influence with 9 related filers | 11.8% | August 13, 2026 |
| Orbimed Advisors LLC13D, may seek influence with 1 related filers | 8.9% | August 18, 2026 |
| Perceptive Advisors LLC13G, passive with 2 related filers | 5.9% | August 14, 2026 |
| Vivo Innovation Fund II Holdings, L.P.13G, passive with 1 related filers | 5.5% | August 17, 2026 |
Largest institutional holders
Insiders
9 insiders reported holding 10,011,473 shares in total, about $145.3M at the last price.
| Holder | Shares |
|---|---|
| Chen BihuaDirector, 10% owner | 3,614,0343,614,034 held indirectly |
| Gordon Carl LDirector | 2,714,2792,714,279 held indirectly |
| Orbimed Advisors LLCDirector | 2,714,2792,714,279 held indirectly |
| Agrawal SundeepDirector | 578,524578,524 held indirectly |
| Liptak Vincent PaulGeneral Counsel | 134,09922,687 held indirectly |
| Li YishanExecutive Chairman, Director, 10% owner | 124,779124,779 held indirectly |
| Cui Jingrong JeanPresident and CEO, Director, 10% owner | 124,779124,779 held indirectly |
| Schmid John P.Director | 6,000 |
| Keyes Jason AChief Financial Officer | 700 |
Questions about BLSM
What does BlossomHill Therapeutics, Inc. do?
BlossomHill Therapeutics, Inc. is a company in the Health care sector.
What is BlossomHill Therapeutics, Inc.'s net worth?
BlossomHill Therapeutics, Inc. has a market value (market cap) of $439M at the latest share price. A company's "net worth" usually means this market value or the shareholders' equity on its balance sheet.
When did BlossomHill Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on September 18, 2026. It covers the period to June 30, 2026.
Similar companies
Compare BLSM with
Follow BLSM
Get an email when BlossomHill Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values BlossomHill Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.